ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
ARS Pharmaceuticals, Inc. reported leadership changes effective July 15, 2026. Richard Lowenthal resigned from the Board of Directors, a step required under his employment agreement and the company’s Change in Control and Severance Benefit Plan to qualify for severance compensation.
On the same date, Chief Medical Officer Sarina Tanimoto, M.D. ceased employment under conditions constituting a termination without cause. In addition to severance described in an earlier proxy statement, the company agreed to pay one-time prorated 2026 target bonus amounts of $217,350 to Lowenthal and $111,780 to Tanimoto, contingent on the effectiveness of their releases of claims.
Positive
- None.
Negative
- Loss of a Board member and the Chief Medical Officer, along with additional prorated bonus payments of $217,350 and $111,780, may disrupt leadership continuity and increase cash outflows.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Additional bonus payment to Richard Lowenthal: $217,350
Additional bonus payment to Sarina Tanimoto, M.D.: $111,780
Effective date of leadership changes: July 15, 2026
3 metrics
Additional bonus payment to Richard Lowenthal
$217,350
One-time prorated 2026 target bonus, contingent on effectiveness of release of claims
Additional bonus payment to Sarina Tanimoto, M.D.
$111,780
One-time prorated 2026 target bonus, contingent on effectiveness of release of claims
Effective date of leadership changes
July 15, 2026
Date when Board resignation and CMO termination without cause became effective
Key Terms
Change in Control and Severance Benefit Plan, termination without cause, release of claims, Definitive Proxy Statement on Schedule 14A
4 terms
Change in Control and Severance Benefit Plan regulatory
"pursuant to the terms of his employment agreement and the Company’s Change in Control and Severance Benefit Plan"
termination without cause regulatory
"ceased employment with the Company under conditions constituting a termination without cause"
release of claims regulatory
"conditioned on the effectiveness of the release of claims provided by each of Mr. Lowenthal and Dr. Tanimoto"
Definitive Proxy Statement on Schedule 14A regulatory
"described under the heading “Employment, Severance, and Change in Control Agreements” in the Company’s Definitive Proxy Statement on Schedule 14A"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What leadership changes at ARS Pharmaceuticals (SPRY) occurred on July 15, 2026?
On July 15, 2026, Richard Lowenthal resigned from the Board of Directors and Sarina Tanimoto, M.D., the Chief Medical Officer, ceased employment under conditions constituting a termination without cause, resulting in significant leadership changes at ARS Pharmaceuticals.
Why did Richard Lowenthal resign from the ARS Pharmaceuticals (SPRY) Board?
Richard Lowenthal’s resignation from the Board was a condition of his right to receive severance compensation under his employment agreement and the company’s Change in Control and Severance Benefit Plan, as previously described in ARS Pharmaceuticals’ proxy disclosure.
How was the departure of CMO Sarina Tanimoto, M.D. at ARS Pharmaceuticals (SPRY) classified?
Sarina Tanimoto, M.D. ceased employment with ARS Pharmaceuticals under conditions constituting a termination without cause. This classification typically entitles an executive to certain severance benefits consistent with the company’s established compensation and severance arrangements.
What additional 2026 bonus payments will ARS Pharmaceuticals (SPRY) make to Lowenthal and Tanimoto?
ARS Pharmaceuticals agreed to pay an additional $217,350 to Richard Lowenthal and $111,780 to Sarina Tanimoto, M.D. These amounts represent prorated portions of their respective target bonuses for 2026, in addition to previously described severance benefits.
What conditions must be met before ARS Pharmaceuticals (SPRY) pays the severance and bonus amounts?
Payment of the severance benefits and additional prorated 2026 bonuses is conditioned on the effectiveness of a release of claims provided by both Richard Lowenthal and Sarina Tanimoto, M.D. in favor of ARS Pharmaceuticals.